Prognostic Value of<i>BRAF </i>and <i>KRAS</i> Mutations in MSI and MSS Stage III Colon Cancer

Abstract

In a pooled analysis of resected stage III colon cancer patients receiving adjuvant FOLFOX, BRAF or KRAS mutations are independently associated with shorter TTR, SAR, and OS in patients with MSS, but not MSI, tumors. Future clinical trials in the adjuvant setting should consider these mutations as important stratification factors.